Glycopyrronium bromide (Sialanar®)

Assessment Status Assessment process complete
Drug Glycopyrronium bromide
Brand Sialanar®
Indication For symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
Assessment Process
Rapid review commissioned 07/03/2017
Rapid review completed 13/04/2017
Rapid review outcome A full HTA is recommended at the submitted price.

Updated June 2017

Following an update to the rapid review of Glycopyrronium bromide (Sialanar®), a full pharmacoeconomic assessment is not recommended.